Docoh
Loading...

36 results

Filter options loading...
Top filers
Top filing types
Recent filing years
8-K
PCSA Processa Pharmaceuticals Inc
10 Jun 21
Submission of Matters to a Vote of Security Holders
5:30pm
compensation are below. In accordance with voting results, the Company will conduct an advisory vote on executive compensation every year. Shares 1 Year 2 … were as follows: Shares For Against Abstain Broker Non-Votes Results of the advisory vote on the frequency of future advisory votes on executive
DEF 14A
PCSA Processa Pharmaceuticals Inc
22 Apr 21
Definitive proxy
2:00pm
elected and qualified; To approve an advisory vote on executive compensation; To conduct an advisory vote on the frequency of future advisory votes … on executive compensation; To approve an amendment and restatement of the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan to increase
10-K/A
2020 FY
PCSA Processa Pharmaceuticals Inc
7 Apr 21
Annual report (amended)
4:23pm
to the code, or any waivers of its requirements, on our website or in a Current Report on Form 8-K. Item 11. Executive Compensation This section … Executive Compensation Philosophy and Design We believe that a skilled, experienced and dedicated executive and senior management team is essential
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
reporting company, we are subject to reduced executive compensation disclosure requirements. Our stockholders and investors may find our common stock less … . Executive Compensation The information required by this Item 11 of Form 10-K is incorporated herein by reference to our 2021 Proxy Statement. Item 12
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
afforded to such companies. For example, as a smaller reporting company, we are subject to reduced executive compensation disclosure requirements. Our
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Sep 20
IPO registration (amended)
4:06pm
. For example, as a smaller reporting company, we are subject to reduced executive compensation disclosure requirements. Our stockholders and investors may
S-1/A
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
company, we are subject to reduced executive compensation disclosure requirements. Our stockholders and investors may find our common stock less attractive
10-K
2019 FY
PCSA Processa Pharmaceuticals Inc
5 Mar 20
Annual report
7:00pm
requirements, on our website or in a Current Report on Form 8-K. Item 11. Executive Compensation Summary Compensation Table The following table
S-1
PCSA Processa Pharmaceuticals Inc
13 Dec 19
IPO registration
5:32pm
, as amended (the “Sarbanes-Oxley Act”); reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements … and registration statements; and exemptions from the requirements of holding non-binding advisory votes on executive compensation or golden parachute
10-Q
2019 Q3
PCSA Processa Pharmaceuticals Inc
14 Nov 19
Quarterly report
11:45am
of the Sarbanes-Oxley Act, the reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements … and the exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments
10-Q
2019 Q2
PCSA Processa Pharmaceuticals Inc
13 Aug 19
Quarterly report
8:00pm
Act, the reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and the exemptions from … the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously
10-Q
2019 Q1
PCSA Processa Pharmaceuticals Inc
14 May 19
Quarterly report
1:08pm
regarding executive compensation in our periodic reports and proxy statements and the exemptions from the requirements of holding a nonbinding advisory vote … on executive compensation and stockholder approval of any golden parachute payments not previously approved. Item 3. Quantitative and Qualitative
DEF 14A
PCSA Processa Pharmaceuticals Inc
26 Apr 19
Definitive proxy
5:02pm
OWNERSHIP OF COMMON STOCK EXECUTIVE COMPENSATION DIRECTOR COMPENSATION TRANSACTIONS WITH RELATED PERSONS, PROMOTERS AND CERTAIN CONTROL PERSONS STOCKHOLDER … stock that will be issued upon the exercise of stock purchase warrants. EXECUTIVE COMPENSATION The following table identifies our current executive
10-K/A
2018 FY
PCSA Processa Pharmaceuticals Inc
5 Apr 19
Annual report (amended)
9:40pm
requirements of Section 404 of the Sarbanes-Oxley Act, the reduced disclosure obligations regarding executive compensation in our periodic reports … and proxy statements and the exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval
10-K
2018 FY
PCSA Processa Pharmaceuticals Inc
28 Mar 19
Annual report
5:25pm
requirements of Section 404 of the Sarbanes-Oxley Act, the reduced disclosure obligations regarding executive compensation in our periodic reports … and proxy statements and the exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval
424B3
PCSA Processa Pharmaceuticals Inc
9 Nov 18
Prospectus supplement
5:04pm
OF BUSINESS DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS EXECUTIVE COMPENSATION SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS … of the Sarbanes-Oxley Act of 2002, as amended (the “Sarbanes-Oxley Act”); reduced disclosure about our executive compensation arrangements in our
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Oct 18
IPO registration (amended)
4:19pm
AND RESULTS OF OPERATIONS DESCRIPTION OF BUSINESS DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS EXECUTIVE COMPENSATION SECURITY OWNERSHIP … -binding advisory votes on executive compensation or golden parachute arrangements. We may take advantage of these provisions for up to five years
S-1/A
PCSA Processa Pharmaceuticals Inc
9 Oct 18
IPO registration (amended)
5:32pm
, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS EXECUTIVE COMPENSATION SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT TRANSACTIONS … -Oxley Act of 2002, as amended (the “Sarbanes-Oxley Act”); reduced disclosure about our executive compensation arrangements in our periodic reports, proxy
S-1/A
PCSA Processa Pharmaceuticals Inc
13 Sep 18
IPO registration (amended)
8:00pm
CONDITION AND RESULTS OF OPERATIONS DESCRIPTION OF BUSINESS DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS EXECUTIVE COMPENSATION SECURITY … requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (the “Sarbanes-Oxley Act”); reduced disclosure about our executive compensation
S-1
PCSA Processa Pharmaceuticals Inc
29 Jul 18
IPO registration
8:00pm
AND CONTROL PERSONS EXECUTIVE COMPENSATION SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT TRANSACTIONS WITH RELATED PERSONS, PROMOTERS … (the “Sarbanes-Oxley Act”); reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements